What is Senti Bio?
Founded in 2016, Senti Bio has developed a sophisticated synthetic biology platform. This platform is engineered to program next-generation cell and gene therapies by utilizing proprietary gene circuits. These circuits, constructed from novel DNA sequences, enable cells to sense inputs, process information, and execute decisions within their biological environments, paving the way for advanced therapeutic applications.
How much funding has Senti Bio raised?
Senti Bio has raised a total of $173.2M across 4 funding rounds:
Series A
$53M
Series B
$105M
Debt
$5.2M
Other Financing Round
$10M
Series A (2018): $53M with participation from Lifeforce Capital Gp I, Amgen Business Development, Goodman Capital, Allen & Company, Pear Ventures, Nest.Bio, New Enterprise Associates, Omega Funds, Lux Capital, 8VC, and Menlo Ventures
Series B (2021): $105M led by Intel Capital, Matrix Partners China, Leaps by Bayer, Mirae Asset Capital Co,Ltd, and Ridgeback Capital
Debt (2022): $5.2M supported by Bayer
Other Financing Round (2025): $10M featuring Celadon Partners
Key Investors in Senti Bio
Celadon Partners
Celadon Partners is an Asian private equity firm specializing in venture capital investments across the Asia-Pacific region, with particular focus on China. The company identifies and invests in transformative innovations that can be applied to traditional industries, aiming to generate long-term returns through intrinsic value investing.
Intel Capital
Founded in 1991, Intel Capital, a division of Intel, invests in innovative startups targeting artificial intelligence, autonomous vehicles, datacenter, Cloud, 5G, next-generation compute, and a wide range of other technologies. Intel Capital curates thousands of business development introductions each year.
Matrix Partners China
Founded in 1977, Matrix Partners operates as a venture capital firm. The Company invests in software and services, communications equipment, semiconductors, storage, internet, and wireless sectors. The company is headquartered in San Francisco, California.
What's next for Senti Bio?
The substantial enterprise-level investment suggests Senti Bio is poised for significant scaling and further development of its innovative cell and gene therapy programming platform. This strategic capital infusion will likely accelerate research and development, expand clinical trial capabilities, and potentially broaden market reach. The company's focus on gene circuits positions it at the forefront of synthetic biology, aiming to revolutionize therapeutic interventions.
See full Senti Bio company page
